USD 35.95
(7.63%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 134.88 Million SGD | 36.85% |
2022 | 98.56 Million SGD | 33.84% |
2021 | 73.64 Million SGD | 50.82% |
2020 | 48.82 Million SGD | -64.99% |
2019 | 139.45 Million SGD | -4.31% |
2018 | 145.73 Million SGD | 2.52% |
2017 | 142.14 Million SGD | 13.27% |
2016 | 125.49 Million SGD | 18.11% |
2015 | 106.24 Million SGD | 17.74% |
2014 | 90.23 Million SGD | 12.85% |
2013 | 79.96 Million SGD | 1.94% |
2012 | 78.43 Million SGD | 8.69% |
2011 | 72.16 Million SGD | -0.97% |
2010 | 72.87 Million SGD | 0.91% |
2009 | 72.22 Million SGD | 0.64% |
2008 | 71.75 Million SGD | 1.36% |
2007 | 70.79 Million SGD | -1.32% |
2006 | 71.74 Million SGD | 1.12% |
2005 | 70.94 Million SGD | 2.64% |
2004 | 69.12 Million SGD | -4.9% |
2003 | 72.67 Million SGD | -1.11% |
2002 | 73.49 Million SGD | -3.5% |
2001 | 76.16 Million SGD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | 32.23 Million SGD | -10.39% |
2024 Q2 | 32.23 Million SGD | 0.0% |
2023 Q1 | 31.47 Million SGD | 34.94% |
2023 Q4 | 35.96 Million SGD | 0.0% |
2023 FY | 134.88 Million SGD | 36.85% |
2023 Q2 | 31.47 Million SGD | 0.0% |
2023 Q3 | 35.96 Million SGD | 14.27% |
2022 Q4 | 23.32 Million SGD | 0.0% |
2022 FY | 98.56 Million SGD | 33.84% |
2022 Q1 | 25.95 Million SGD | -33.76% |
2022 Q2 | 51.91 Million SGD | 100.0% |
2022 Q3 | 23.32 Million SGD | -55.07% |
2021 Q1 | 17.22 Million SGD | 228.26% |
2021 Q4 | 39.18 Million SGD | 100.0% |
2021 Q3 | 19.59 Million SGD | -43.13% |
2021 Q2 | 34.45 Million SGD | 100.0% |
2021 FY | 73.64 Million SGD | 50.82% |
2020 Q1 | 21.78 Million SGD | -3.2% |
2020 Q3 | 2.62 Million SGD | -93.98% |
2020 FY | 48.82 Million SGD | -64.99% |
2020 Q4 | 5.24 Million SGD | 100.0% |
2020 Q2 | 43.57 Million SGD | 100.0% |
2019 FY | 139.45 Million SGD | -4.31% |
2019 Q4 | 22.51 Million SGD | -30.71% |
2019 Q3 | 32.48 Million SGD | -20.49% |
2019 Q2 | 40.85 Million SGD | -6.28% |
2019 Q1 | 43.59 Million SGD | 39.09% |
2018 Q1 | 38.17 Million SGD | 24.87% |
2018 Q4 | 31.34 Million SGD | -15.3% |
2018 Q3 | 37 Million SGD | -5.59% |
2018 Q2 | 39.2 Million SGD | 2.67% |
2018 FY | 145.73 Million SGD | 2.52% |
2017 FY | 142.14 Million SGD | 13.27% |
2017 Q4 | 30.57 Million SGD | -10.17% |
2017 Q3 | 34.03 Million SGD | -12.12% |
2017 Q2 | 38.73 Million SGD | -0.19% |
2017 Q1 | 38.8 Million SGD | 31.89% |
2016 Q4 | 29.42 Million SGD | -9.19% |
2016 FY | 125.49 Million SGD | 18.11% |
2016 Q3 | 32.39 Million SGD | 3.52% |
2016 Q2 | 31.29 Million SGD | -3.35% |
2016 Q1 | 32.37 Million SGD | 73.56% |
2015 FY | 106.24 Million SGD | 17.74% |
2015 Q4 | 18.65 Million SGD | -35.02% |
2015 Q3 | 28.7 Million SGD | -8.38% |
2015 Q2 | 31.33 Million SGD | 13.75% |
2015 Q1 | 27.54 Million SGD | 53.0% |
2014 Q3 | 22.1 Million SGD | -18.56% |
2014 Q4 | 18 Million SGD | -18.56% |
2014 Q1 | 22.97 Million SGD | 38.02% |
2014 FY | 90.23 Million SGD | 12.85% |
2014 Q2 | 27.14 Million SGD | 18.15% |
2013 Q1 | 18.42 Million SGD | -1.79% |
2013 Q3 | 21.39 Million SGD | -8.92% |
2013 Q2 | 23.49 Million SGD | 27.53% |
2013 FY | 79.96 Million SGD | 1.94% |
2013 Q4 | 16.64 Million SGD | -22.2% |
2012 Q1 | 18.68 Million SGD | 4.16% |
2012 Q3 | 19.91 Million SGD | -5.55% |
2012 Q4 | 18.75 Million SGD | -5.8% |
2012 FY | 78.43 Million SGD | 8.69% |
2012 Q2 | 21.08 Million SGD | 12.82% |
2011 Q4 | 17.93 Million SGD | -6.11% |
2011 Q1 | 17.52 Million SGD | 5.09% |
2011 Q2 | 17.59 Million SGD | 0.35% |
2011 FY | 72.16 Million SGD | -0.97% |
2011 Q3 | 19.1 Million SGD | 8.61% |
2010 Q2 | 19.96 Million SGD | 14.32% |
2010 Q4 | 16.68 Million SGD | -11.11% |
2010 FY | 72.87 Million SGD | 0.91% |
2010 Q3 | 18.76 Million SGD | -6.01% |
2010 Q1 | 17.46 Million SGD | -3.03% |
2009 Q1 | 16.04 Million SGD | 0.0% |
2009 Q4 | 18.01 Million SGD | -8.64% |
2009 Q3 | 19.71 Million SGD | 6.82% |
2009 Q2 | 18.45 Million SGD | 15.04% |
2009 FY | 72.22 Million SGD | 0.64% |
2008 FY | 71.75 Million SGD | 1.36% |
2007 FY | 70.79 Million SGD | -1.32% |
2006 FY | 71.74 Million SGD | 1.12% |
2005 FY | 70.94 Million SGD | 2.64% |
2004 FY | 69.12 Million SGD | -4.9% |
2003 FY | 72.67 Million SGD | -1.11% |
2002 FY | 73.49 Million SGD | -3.5% |
2002 Q2 | 33.72 Million SGD | 0.0% |
2002 Q4 | 39.77 Million SGD | 0.0% |
2001 FY | 76.16 Million SGD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
AstraZeneca PLC | 34.69 Billion USD | 99.611% |
Bristol-Myers Squibb Company PFD CONV 2 | 34.31 Billion USD | 99.607% |
CSPC Pharmaceutical Group Limited | 30.13 Billion USD | 99.552% |
Clarus Therapeutics Holdings, Inc. | 11.23 Million USD | -1100.392% |
Novartis AG | 34.18 Billion USD | 99.605% |
PT Kalbe Farma Tbk. | 743.47 Million USD | 81.857% |